GOSS vs. CDTX, TVTX, AUPH, BHVN, SDGR, EWTX, EVO, ABCL, JANX, and ARDX
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Cidara Therapeutics (CDTX), Travere Therapeutics (TVTX), Aurinia Pharmaceuticals (AUPH), Biohaven (BHVN), Schrodinger (SDGR), Edgewise Therapeutics (EWTX), Evotec (EVO), AbCellera Biologics (ABCL), Janux Therapeutics (JANX), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry.
Gossamer Bio vs. Its Competitors
Gossamer Bio (NASDAQ:GOSS) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.
Gossamer Bio currently has a consensus target price of $8.50, suggesting a potential upside of 335.90%. Cidara Therapeutics has a consensus target price of $64.14, suggesting a potential downside of 1.36%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Cidara Therapeutics.
In the previous week, Gossamer Bio and Gossamer Bio both had 2 articles in the media. Cidara Therapeutics' average media sentiment score of 0.67 beat Gossamer Bio's score of 0.50 indicating that Cidara Therapeutics is being referred to more favorably in the news media.
Gossamer Bio has higher revenue and earnings than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Gossamer Bio has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.
Cidara Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -344.81%. Cidara Therapeutics' return on equity of -50.81% beat Gossamer Bio's return on equity.
81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 6.7% of Gossamer Bio shares are owned by company insiders. Comparatively, 7.6% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Cidara Therapeutics beats Gossamer Bio on 9 of the 16 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GOSS) was last updated on 8/20/2025 by MarketBeat.com Staff
MarketBeat All Access